Bank of America’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bank of America’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-9,300	Closed	-$157K	–	7688
2014 Q4	$157K	Sell	9,300 -2,500	-21%	-$36.4K	﹤0.01%	5558
2014 Q3	$158K	Buy	11,800 +6,800	+136%	+$81K	﹤0.01%	5608
2014 Q2	$64K	Buy	5,000 +500	+11%	+$5.21K	﹤0.01%	6477
2014 Q1	$54K	Sell	4,500 -10,500	-70%	-$141K	﹤0.01%	6372
2013 Q4	$207K	Buy	15,000 +6,900	+85%	+$97.4K	﹤0.01%	5570
2013 Q3	$141K	Buy	8,100 +2,300	+40%	+$44K	﹤0.01%	5736
2013 Q2	$94K	Buy	+5,800	New	+$179K	﹤0.01%	6204

Other funds holding INFI

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Bank of America's INFI Position: Q3 2023 in Review

Bank of America sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 758 shares — an estimated $159 sold.

Bank of America first reported a position in INFI in Q2 2013 and held it in 41 quarters. The position peaked at $968K in Q2 2013. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.

Bank of America reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Bank of America sold 758 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $159.
Bank of America first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
Bank of America's Infinity Pharmaceuticals, Inc. position peaked at $968K in Q2 2013.
3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.

Based on Bank of America's 13F filing for Q3 2023, filed 14 Nov 2023.